Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

Tesamorelin vs CJC-1295 + Ipamorelin

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

Tesamorelin has stronger documented evidence (FDA-Approved) than CJC-1295 + Ipamorelin (Anecdotal + Animal Studies) while both occupy the ghrh / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, Tesamorelin is the safer pick. CJC-1295 + Ipamorelin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

Tesamorelin

FDA-Approved

CJC-1295 + Ipamorelin

Anecdotal + Animal Studies

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Shared safety considerations

Both compounds share these reported concerns: injection site reactions. Open each peptide page for the full risk paragraph and source citations.

Side-by-side

Tesamorelin CJC-1295 + Ipamorelin
Class GHRH analog (FDA-approved) GHRH analog + selective GHRP blend (GH-secretagogue stack)
Drug class Growth Hormone Secretion Growth Hormone Secretion
Mechanism Binds pituitary GHRH receptor to stimulate pulsatile endogenous GH secretion Dual-receptor stimulation: CJC-1295 (no-DAC) binds the pituitary GHRH receptor while Ipamorelin agonises the ghrelin / GHS-R1a receptor. Co-administration amplifies the natural GH pulse with a cleaner side-effect profile vs GHRP-2/6 (negligible cortisol or prolactin rise from the GHRP arm).
Route SC injection SC injection
Half-life ~26 min CJC-1295 no-DAC ~30 min; Ipamorelin ~2 hrs
Dosage (research) 2 mg SC daily (FDA label) 100 mcg of each component SC nightly (5 nights/wk); some protocols use 200 mcg of each pre-sleep. Cycle 8-12 weeks on / 4 weeks off
Evidence tier FDA-Approved Anecdotal + Animal Studies
Research depth 127 indexed (PubMed 84 · CT 23 · EPMC 20) 5 indexed (PubMed 0 · CT 0 · EPMC 5)
Availability Prescription Compounding Restricted
Reported risks Injection site reactions; hyperglycemia; joint pain; edema; elevated IGF-1 Receptor desensitisation with chronic daily dosing; mild water retention; injection site reactions; theoretical IGF-1 elevation with high-frequency dosing; not FDA-approved for any indication

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick Tesamorelin or CJC-1295 + Ipamorelin?

Tesamorelin has stronger documented evidence (FDA-Approved) than CJC-1295 + Ipamorelin (Anecdotal + Animal Studies) while both occupy the ghrh / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, Tesamorelin is the safer pick. CJC-1295 + Ipamorelin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between Tesamorelin and CJC-1295 + Ipamorelin?

Tesamorelin is classed as GHRH analog (FDA-approved); CJC-1295 + Ipamorelin is classed as GHRH analog + selective GHRP blend (GH-secretagogue stack). Reported mechanism: Tesamorelin, Binds pituitary GHRH receptor to stimulate pulsatile endogenous GH secretion; CJC-1295 + Ipamorelin, Dual-receptor stimulation: CJC-1295 (no-DAC) binds the pituitary GHRH receptor while Ipamorelin agonises the ghrelin / GHS-R1a receptor. Co-administration amplifies the natural GH pulse with a cleaner side-effect profile vs GHRP-2/6 (negligible cortisol or prolactin rise from the GHRP arm). Reported half-life: Tesamorelin, ~26 min; CJC-1295 + Ipamorelin, CJC-1295 no-DAC ~30 min; Ipamorelin ~2 hrs. Routes in published studies: Tesamorelin, SC injection; CJC-1295 + Ipamorelin, SC injection.

Which has stronger evidence, Tesamorelin or CJC-1295 + Ipamorelin?

Tesamorelin has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Tesamorelin is graded FDA-Approved, with 13 cited sources on its reference page and 127 indexed studies. CJC-1295 + Ipamorelin is graded Anecdotal + Animal Studies, with 3 cited sources on its reference page and 5 indexed studies.

Which is more accessible, Tesamorelin or CJC-1295 + Ipamorelin?

Tesamorelin is FDA-approved and CJC-1295 + Ipamorelin is not. Catalog status: Tesamorelin, Prescription; CJC-1295 + Ipamorelin, Compounding Restricted.

Are Tesamorelin and CJC-1295 + Ipamorelin ever combined?

Tesamorelin and CJC-1295 + Ipamorelin appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…